Read by QxMD icon Read


Andrea F D Di Stefano, Antonio Rusca, Milko M Radicioni, Luca Loprete, Daniela Binelli, Giorgio Caccia, Barbara Cometti
BACKGROUND AND OBJECTIVE: Highly purified human menotrophin and urofollitrophin preparations obtained from human urine via a novel patented purification method have been tested over a timeframe of 14 years in the studies presented in this article. The objective of the studies was to investigate the pharmacokinetics and the pharmacodynamics of follicle-stimulating hormone (FSH) after single subcutaneous and intramuscular doses and multiple subcutaneous doses of the tested preparations in healthy fertile pituitary-suppressed women...
December 2016: Clinical Drug Investigation
Xuefeng Lu, Qiuju Chen, Yonglun Fu, Ai Ai, Qifeng Lyu, Yan Ping Kuang
To demonstrate the incidence and effects of elevated progesterone (P) on the trigger day on the outcome of in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles using Medroxyprogesterone acetate (MPA) co-treated with Human Menotrophins Gonadotrophin (hMG + MPA), we performed a retrospective analysis including 4106 IVF/ICSI cycles. The cycles were grouped according to the P level on the trigger day: <1 ng/mL, between 1-1.5 ng/ml (including 1), between 1.5-2 ng/mL (including 1...
2016: Scientific Reports
Maged Mohammed Yassin, Fadel Akram Sharif, Mohammed Marwan Laqqan
UNLABELLED: Back ground: Careful evaluation of patients and proper treatment with right techniques are essential for successful outcome of assisted reproduction. To obtain satisfactory results, it is necessary to assess ovarian reserve before planning treatment. OBJECTIVE: To evaluate anti-mullerian hormone as a predictor of fertility potential in terms of ovarian reserve and ovarian response reflected by antral follicles and mature oocyte counts in response to menotrophin stimulation in in vitro fertilization (IVF) women from Gaza Strip...
April 2013: Iranian Journal of Reproductive Medicine
Jackie Ferguson, Jason Hockley, Richard Tiplady, Chris Burns
The potencies of therapeutic preparations of gonadotrophins of human, urinary origin, which comprise a heterogenous mix of isoforms with follicle-stimulating hormone (FSH) and luteinizing hormone (LH) bioactivities, are standardized by WHO International Standards (IS). We report here, the evaluation, through an international collaborative study, of a candidate preparation, coded 10/286, to replace the 4th IS, 98/704, for human, urinary FSH and LH (Menotrophin) which has been used for many years for the potency assignment of therapeutic preparations using bioassays...
November 2013: Biologicals: Journal of the International Association of Biological Standardization
Joan-Carles Arce, Johan Smitz
The aim of this retrospective study was to investigate the impact of endogenous and exogenous luteinizing hormone (LH) activity on treatment outcome, when taking into consideration potential confounding variables. Data were derived from IVF patients (n = 358) stimulated with highly purified menotrophin (HP-hMG) in a long gonadotrophin-releasing hormone (GnRH) agonist protocol. Simple retrospective logistic regression analysis showed that the mid-follicular exogenous concentrations of human chorionic gonadotrophin (hCG) (p = 0...
January 2013: Gynecological Endocrinology
Ellen Anckaert, Johan Smitz, Johan Schiettecatte, Bjarke M Klein, Joan-Carles Arce
BACKGROUND: This study evaluated the predictive value of serum and follicular fluid (FF) concentrations of anti-Müllerian hormone (AMH) with respect to treatment outcome variables in an IVF cycle. METHODS: A retrospective analysis was performed with data from 731 normogonadotrophic women undergoing controlled ovarian stimulation after stimulation with highly purified menotrophin (HP-hMG) or rFSH following a long GnRH agonist protocol. RESULTS: In both treatment groups, the serum AMH concentration at the start of the stimulation was significantly (P < 0...
June 2012: Human Reproduction
Anders Nyboe Andersen
After the introduction of recombinant FSH preparations for IVF or intracytoplasmic sperm injection (ICSI), it became clear that good pregnancy rates could be achieved with or without any exogenous LH, irrespective of the protocol used. Both recombinant LH- and human chorionic gonadotrophin (HCG)-containing menotrophins are available, so biology and pharmacology could be nicely linked, if the following concept could be documented: subgroups of patients have low circulating LH concentrations, and thus low pregnancy rates, and when such patients were co-treated with recombinant LH, the pregnancy rates would increase...
December 2011: Reproductive Biomedicine Online
Julián Ruiz Anguas, Everardo Anta Jaen, Leonor Durán Monterrosas, Alberto Kably Ambe
OBJECTIVE: To compare double homologous versus only one intrauterine insemination (IUI) by stimulated cycle. PATIENTS AND METHOD: In a prospective, comparative study 138 patients were included, who underwent to intrauterine insemination; not inclusion parameters were: patients with cancelled cycles by poor response or by ovarian hyperestimulation syndrome risk. Patients were divided in two groups: Group 1 (N = 69) one insemination at 36 hours after human gonadotrophin chorionic hormone (hCG) and group 2 (N = 69) two inseminations 24 and 48 hours after hCG...
February 2005: Ginecología y Obstetricia de México
S Wathlet, T Adriaenssens, I Segers, G Verheyen, H Van de Velde, W Coucke, R Ron El, P Devroey, J Smitz
BACKGROUND: Cumulus cell (CC) gene expression is suggested as a non-invasive analysis method to predict oocyte competence. There are, however, important between-patient differences in CC gene expression. These can be compensated when expression results are combined with patient and cycle characteristics using a multiple regression analysis model. METHODS: From ICSI patients stimulated with GnRH antagonist and recombinant FSH (n= 25) or GnRH agonist and highly purified menotrophin (n= 20), CC were collected and oocytes were individually fertilized and cultured...
May 2011: Human Reproduction
Sverre Bjercke, Tom Tanbo, Thomas Abyholm, Anne Omland, Hans Kristian Opøien, Peter Fedorcsak
OBJECTIVE: To test whether the clinical efficiency of recombinant FSH (rFSH) and highly purified human menotrophin (hMG) differs in terms of pregnancy and live birth rates during the first treatment cycle of IVF or ICSI. DESIGN: Prospective cohort study. SETTING: Department of Gynecology and Obstetrics, Rikshospitalet, Oslo University Hospital. STUDY POPULATION: Records of 1,136 infertile couples undergoing their first IVF (n = 682) or ICSI (n = 454) treatments were reviewed...
August 2010: Acta Obstetricia et Gynecologica Scandinavica
Eliana Garalejić, Biljana Arsić, Dragana Bojović-Jović, Milija Veljković, Biljana Macanović, Dejan Pavlović, Bojan Vasić, Dragana Lekić
INTRODUCTION: Anal atresia is a congenital anomaly, very life-threatening and urgent. Surgical treatment of this anomaly consists of colostomy first, and then of anal reconstruction. CASE REPORT: We presented a 31-year old female with the surgery treatment of anal atresia in the early childhood. In the reproductive period, due to tubal infertily, the patient was included in the program of in vitro fertilization (IVF), in the Clinic for Gynecology and Obstetrics "Narodni front", Belgrade...
March 2010: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
Masoud Afnan
Fertility treatment strives for the delivery of a healthy live birth. Human menopausal gonadotrophin (HMG) and recombinant FSH (rFSH) are the two types of gonadotrophin currently used for ovarian stimulation in assisted reproduction treatments. Although both HMG and rFSH have been shown to be effective, a number of studies have examined whether a potential difference in clinical benefit or outcome exists between treatments. Unlike rFSH preparations, HMG contains both FSH and LH activity (in the form of LH and human chorionic gonadotrophin, which are short- and long-acting, respectively)...
2009: Reproductive Biomedicine Online
Søren Ziebe, Kersti Lundin, Ronny Janssens, Lisbeth Helmgaard, Joan-Carles Arce
BACKGROUND: There are limited data on the impact of different gonadotrophin preparations on embryo quality. METHODS: This evaluation was part of a randomized, assessor-blind, multinational trial, conducted in 731 women undergoing IVF after stimulation with highly purified human menopausal gonadotropin (HP-hMG; MENOPUR) (n = 363) or recombinant FSH (rFSH; GONAL-F) (n = 368). Ongoing pregnancy was the primary end-point [HP-hMG 27% and rFSH 22%; odds ratio (OR) (95% confidence interval, CI) 1...
September 2007: Human Reproduction
Peter Bo Poulsen, Astrid Højgaard, Jens Piero Quartarolo
INTRODUCTION: There is a choice between two types of hormones for stimulation of the follicles in IVF treatment - recombinant FSH and the urine-derived menotrophin. A literature review by NICE (2004) in the United Kingdom documented that the two types of hormones were equally effective and safe, which is why it was recommended to use the cheaper urine-derived hormone. Based on the EISG study (European and Israeli Study Group), the aim was to analyse the health economic consequences of the choice between the two types of hormone in IVF treatment in Denmark...
April 2, 2007: Ugeskrift for Laeger
J Smitz, A N Andersen, P Devroey, J-C Arce
BACKGROUND: Highly purified menotrophin (HP-hMG) has been associated with fewer oocytes retrieved and a higher proportion of top-quality embryos compared with recombinant FSH (rFSH). METHODS: A randomized, assessor-blind, multinational trial in 731 women undergoing IVF after stimulation with HP-hMG (MENOPUR) (n = 363) or rFSH (GONAL-F) (n = 368) following a long GnRH agonist protocol was conducted. Blood was collected before, during and after stimulation. Fluid was collected from follicles > or =17 mm...
March 2007: Human Reproduction
A H Balen, P Platteau, A N Andersen, P Devroey, P Sørensen, L Helmgaard, J-C Arce
OBJECTIVE: To assess the influence of body weight on the outcome of ovulation induction in women with World Health Organization (WHO) group II anovulatory infertility. DESIGN: The combined results of two studies in which either a highly purified urinary follicle-stimulating hormone or highly purified urinary menotrophin were compared with recombinant follicle-stimulating hormone. SETTING: Thirty-six fertility clinics. POPULATION: A total of 335 women with WHO group II anovulatory infertility failing to ovulate or conceive on clomifene citrate...
October 2006: BJOG: An International Journal of Obstetrics and Gynaecology
Anders Nyboe Andersen, Paul Devroey, Joan-Carles Arce
BACKGROUND: LH activity may influence treatment response and outcome in IVF cycles. METHODS: A randomized, assessor-blind, multinational trial compared ongoing pregnancy rates (primary end-point) in 731 women undergoing IVF after stimulation with highly purified menotrophin (HP-hMG) (n = 363) or recombinant FSH (rFSH) (n = 368) following a long GnRH agonist protocol. Patients received identical pre- and post-randomization interventions. One or two embryos were transferred on day 3...
December 2006: Human Reproduction
K Lossl, A N Andersen, A Loft, N L C Freiesleben, S Bangsbøll, C Yding Andersen
BACKGROUND: Temporary exposure of follicles to increased levels of androgens may enhance their sensitivity to FSH. The aim of this study was to increase the intraovarian androgen level using aromatase inhibitors and hCG before controlled ovarian stimulation (COH) and to test this concept clinically. METHODS: In a prospective, non-randomized study, 45 patients were treated in modified antagonist protocols including early-follicular-phase down-regulation and androgen priming before COH...
October 2006: Human Reproduction
Peter Platteau, Anders Nyboe Andersen, Adam Balen, Paul Devroey, Per Sørensen, Lisbeth Helmgaard, Joan-Carles Arce
BACKGROUND: The contribution of the LH activity in menotrophin preparations for ovulation induction has been investigated in small trials conducted versus FSH preparations. The objective of this study was to demonstrate non-inferiority of highly purified urinary menotrophin (HP-HMG) versus recombinant FSH (rFSH) with respect to the primary outcome measure, ovulation rate. METHODS: This was a randomized, open-label, assessor-blind, multinational study. Women with anovulatory infertility WHO Group II and resistant to clomiphene citrate were randomized (computer-generated list) to stimulation with HP-HMG (n=91) or rFSH (n=93) using a low-dose step-up protocol...
July 2006: Human Reproduction
S Toporcerová, R Hredzák, A Ostró, V Zdilová, D Potoceková
OBJECTIVE: To evaluate the effect of exogenous luteinizing hormone in in vitro fertilization cycles with depot GnRH agonist and low residual LH levels. DESIGN: Prospective randomized clinical trial. SETTING: 2nd Department of Gynecology and Obstetrics, Medical Faculty and L. Pasteur University Hospital Kosice METHODS: In the prospective randomized clinical trial the effect of exogenous LH on outcomes of assisted reproduction was evaluated...
May 2005: Ceská Gynekologie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"